Bruker’s (BRKR) “Buy” Rating Reaffirmed at Guggenheim

Bruker (NASDAQ:BRKR)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research note issued on Monday,Benzinga reports.

A number of other analysts have also recently commented on the stock. Citigroup lowered their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Stifel Nicolaus lowered their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Wells Fargo & Company dropped their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and an average target price of $70.50.

Bruker Stock Up 2.0 %

NASDAQ BRKR traded up $1.02 during trading on Monday, reaching $51.84. 150,840 shares of the company’s stock traded hands, compared to its average volume of 1,604,865. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a market cap of $7.86 billion, a price-to-earnings ratio of 67.77, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16. The company’s 50 day simple moving average is $56.73 and its two-hundred day simple moving average is $60.03.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, sell-side analysts forecast that Bruker will post 2.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Bruker

Institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System boosted its holdings in Bruker by 11.3% during the 3rd quarter. Louisiana State Employees Retirement System now owns 30,600 shares of the medical research company’s stock valued at $2,113,000 after acquiring an additional 3,100 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Bruker by 109.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 13,110 shares of the medical research company’s stock valued at $905,000 after purchasing an additional 6,863 shares in the last quarter. Boston Trust Walden Corp purchased a new stake in Bruker during the 3rd quarter worth approximately $207,000. DekaBank Deutsche Girozentrale boosted its position in Bruker by 32.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 307,040 shares of the medical research company’s stock valued at $21,516,000 after buying an additional 75,220 shares during the period. Finally, State of Alaska Department of Revenue grew its stake in shares of Bruker by 5.6% in the third quarter. State of Alaska Department of Revenue now owns 42,686 shares of the medical research company’s stock worth $2,947,000 after acquiring an additional 2,245 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.